JP6411491B2 - 多環式カルバモイルピリドン化合物およびｈｉｖ感染症を処置するためのその使用 - Google Patents
多環式カルバモイルピリドン化合物およびｈｉｖ感染症を処置するためのその使用 Download PDFInfo
- Publication number
- JP6411491B2 JP6411491B2 JP2016525819A JP2016525819A JP6411491B2 JP 6411491 B2 JP6411491 B2 JP 6411491B2 JP 2016525819 A JP2016525819 A JP 2016525819A JP 2016525819 A JP2016525819 A JP 2016525819A JP 6411491 B2 JP6411491 B2 JP 6411491B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- independently hydrogen
- alkyl
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CNC1(*)C(*)C1* Chemical compound CNC1(*)C(*)C1* 0.000 description 5
- JAPMJSVZDUYFKL-OLQVQODUSA-N C1[C@@H]2[C@H]1CCC2 Chemical compound C1[C@@H]2[C@H]1CCC2 JAPMJSVZDUYFKL-OLQVQODUSA-N 0.000 description 1
- ZALVPHROCCRSES-UHFFFAOYSA-N COC(C(N(CC(O)O)C=C(C(NCc(ccc(F)c1)c1F)=O)C1=O)=C1OC)=O Chemical compound COC(C(N(CC(O)O)C=C(C(NCc(ccc(F)c1)c1F)=O)C1=O)=C1OC)=O ZALVPHROCCRSES-UHFFFAOYSA-N 0.000 description 1
- XPBVFWUQOQKKLA-UHFFFAOYSA-N COC(CN(C=C(C(NCc(c(F)c1)ccc1F)=O)C1=O)C(C(OC)=O)=C1OC)OC Chemical compound COC(CN(C=C(C(NCc(c(F)c1)ccc1F)=O)C1=O)C(C(OC)=O)=C1OC)OC XPBVFWUQOQKKLA-UHFFFAOYSA-N 0.000 description 1
- NVFYBKXLJMLXPJ-DASAFIRZSA-N COC1=C(C(N2[C@@H](C3)OC4[C@H](C5)[C@H]5C2C4)=O)N3C=C(C(N[C@H](C(F)(F)F)c(c(F)c2)ccc2F)=O)C1=O Chemical compound COC1=C(C(N2[C@@H](C3)OC4[C@H](C5)[C@H]5C2C4)=O)N3C=C(C(N[C@H](C(F)(F)F)c(c(F)c2)ccc2F)=O)C1=O NVFYBKXLJMLXPJ-DASAFIRZSA-N 0.000 description 1
- BIDXLSWFQBSJTN-QHRCKUMJSA-N C[C@H]([C@@H]1C2C3)[C@H]1C3O[C@H](CN(C=C(C(N[C@H](C(F)(F)F)c(ccc(F)c1)c1F)=O)C1=O)C3=C1O)N2C3=O Chemical compound C[C@H]([C@@H]1C2C3)[C@H]1C3O[C@H](CN(C=C(C(N[C@H](C(F)(F)F)c(ccc(F)c1)c1F)=O)C1=O)C3=C1O)N2C3=O BIDXLSWFQBSJTN-QHRCKUMJSA-N 0.000 description 1
- YBYOYSBHGOPJMG-FTLRAWMYSA-N OC1=C(C(N2C(C3)O[C@H]4C[C@@H]2CC4)=O)N3C=C(C(NCc(c(F)c2)ccc2F)=O)C1=O Chemical compound OC1=C(C(N2C(C3)O[C@H]4C[C@@H]2CC4)=O)N3C=C(C(NCc(c(F)c2)ccc2F)=O)C1=O YBYOYSBHGOPJMG-FTLRAWMYSA-N 0.000 description 1
- VPOQYEARYQADOC-ZNIKTOSDSA-N OC1=C(C(N2[C@@H](C3)OC4[C@@H](C5)C5[C@@H]2C4)=O)N3C=C(C(N[C@H](C(F)(F)F)c(c(F)c2)ccc2F)=O)C1=O Chemical compound OC1=C(C(N2[C@@H](C3)OC4[C@@H](C5)C5[C@@H]2C4)=O)N3C=C(C(N[C@H](C(F)(F)F)c(c(F)c2)ccc2F)=O)C1=O VPOQYEARYQADOC-ZNIKTOSDSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361845806P | 2013-07-12 | 2013-07-12 | |
| US61/845,806 | 2013-07-12 | ||
| PCT/US2014/046413 WO2015006731A1 (en) | 2013-07-12 | 2014-07-11 | Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016527217A JP2016527217A (ja) | 2016-09-08 |
| JP2016527217A5 JP2016527217A5 (enExample) | 2017-08-24 |
| JP6411491B2 true JP6411491B2 (ja) | 2018-10-24 |
Family
ID=51257629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016525819A Active JP6411491B2 (ja) | 2013-07-12 | 2014-07-11 | 多環式カルバモイルピリドン化合物およびｈｉｖ感染症を処置するためのその使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US9421214B2 (enExample) |
| EP (2) | EP3252058B1 (enExample) |
| JP (1) | JP6411491B2 (enExample) |
| AU (3) | AU2014286993B2 (enExample) |
| CA (1) | CA2916993C (enExample) |
| CY (1) | CY1119544T1 (enExample) |
| DK (1) | DK3019503T3 (enExample) |
| ES (2) | ES2645192T3 (enExample) |
| HR (1) | HRP20171808T1 (enExample) |
| HU (1) | HUE037347T2 (enExample) |
| LT (1) | LT3019503T (enExample) |
| NO (1) | NO3011851T3 (enExample) |
| PL (2) | PL3019503T3 (enExample) |
| PT (2) | PT3252058T (enExample) |
| RS (1) | RS56540B1 (enExample) |
| SI (2) | SI3019503T1 (enExample) |
| SM (1) | SMT201700498T1 (enExample) |
| WO (1) | WO2015006731A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA037633B1 (ru) * | 2012-12-21 | 2021-04-23 | Джилид Сайэнс, Инк. | Полициклические карбамоилпиридоновые соединения, их фармацевтические композиции и применение |
| NO2865735T3 (enExample) | 2013-07-12 | 2018-07-21 | ||
| CA2916993C (en) * | 2013-07-12 | 2019-01-15 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| WO2016027879A1 (ja) | 2014-08-22 | 2016-02-25 | 塩野義製薬株式会社 | インテグラーゼ阻害活性を有する多環性ピリドン誘導体 |
| RS56787B1 (sr) | 2015-03-04 | 2018-04-30 | Gilead Sciences Inc | Toll-like receptor koji modulira jedinjenja 4,6-diamino-pirido[3,2-d]pirimidina |
| TR201905009T4 (tr) * | 2015-04-02 | 2019-05-21 | Gilead Sciences Inc | Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları. |
| EP3341373A1 (en) | 2015-08-26 | 2018-07-04 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
| CA2997955A1 (en) | 2015-09-15 | 2017-03-23 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of hiv |
| WO2018044838A1 (en) * | 2016-08-31 | 2018-03-08 | Viiv Healthcare Company | Combinations and uses and treatments thereof |
| JP2019528304A (ja) * | 2016-08-31 | 2019-10-10 | ヴィーブ ヘルスケア カンパニー | 組み合わせ並びにその使用及び治療 |
| US10370342B2 (en) | 2016-09-02 | 2019-08-06 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
| CR20230571A (es) | 2018-05-31 | 2024-01-22 | Shionogi & Co | DERIVADO POLICÍCLICO DE CARBAMOILPIRIDONA (divisional 2020-0644) |
| EP3805221A4 (en) | 2018-05-31 | 2022-01-05 | Shionogi & Co., Ltd | POLYCYCLIC PYRIDONE DERIVATIVE |
| CN113874079B (zh) | 2019-03-22 | 2024-11-08 | 吉利德科学公司 | 桥连三环氨基甲酰基吡啶酮化合物及其药学用途 |
| US20220305115A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| US20200398978A1 (en) | 2019-06-20 | 2020-12-24 | Bell Helicopter Textron Inc. | Low-drag rotor blade extension |
| US11248005B2 (en) | 2019-07-08 | 2022-02-15 | Lupin Limited | Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor |
| US20230059640A1 (en) | 2019-11-28 | 2023-02-23 | Shionogi & Co., Ltd. | Prophylactic and therapeutic pharmaceutical agent for hiv infectious diseases characterized by comprising combination of integrase inhibitor and anti-hiv agent |
| EP4110783A1 (en) | 2020-02-24 | 2023-01-04 | Gilead Sciences, Inc. | Tetracyclic compounds for treating hiv infection |
| WO2022072520A1 (en) * | 2020-09-30 | 2022-04-07 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| DK4196479T5 (da) | 2021-01-19 | 2025-01-02 | Gilead Sciences Inc | Substituerede pyridotriazinforbindelser og anvendelser deraf |
| TWI843506B (zh) | 2022-04-06 | 2024-05-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE788516A (fr) | 1971-09-10 | 1973-03-07 | Lonza Ag | Procede de fabrication d'esters alcoxyacetylacetiques |
| GB1528382A (en) | 1974-12-26 | 1978-10-11 | Teijin Ltd | Cyclopentene diols and acyl esters thereof and processes for their preparation |
| DE2658401A1 (de) | 1976-12-23 | 1978-07-06 | Merck Patent Gmbh | Cyclopentan-1-amine, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel |
| US4575694A (en) | 1984-03-05 | 1986-03-11 | Allied Corporation | Coaxial connector |
| DE3900735A1 (de) | 1989-01-12 | 1990-07-26 | Hoechst Ag | Neue mehrfunktionelle (alpha)-diazo-(beta)-ketoester, verfahren zu ihrer herstellung und deren verwendung |
| US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
| US6642245B1 (en) | 1990-02-01 | 2003-11-04 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
| US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| DE4014649A1 (de) | 1990-05-08 | 1991-11-14 | Hoechst Ag | Neue mehrfunktionelle verbindungen mit (alpha)-diazo-ss-ketoester- und sulfonsaeureester-einheiten, verfahren zu ihrer herstellung und deren verwendung |
| GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| SE9702772D0 (sv) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
| US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| AU1403099A (en) | 1997-11-14 | 1999-06-07 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
| JP2002529455A (ja) | 1998-11-09 | 2002-09-10 | ジェームズ・ブラック・ファウンデーション・リミテッド | ガストリンおよびコレシストキニン受容体リガンド類 |
| GB2345058A (en) | 1998-12-01 | 2000-06-28 | Cerebrus Pharm Ltd | Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system |
| DE69939749D1 (de) | 1998-12-25 | 2008-11-27 | Shionogi & Co | Aromatische heterocyclen mit hiv integrase inhibierenden eigenschaften |
| AU2001262732A1 (en) | 2000-06-14 | 2001-12-24 | Shionogi And Co., Ltd. | Inhibitor for enzyme having two divalent metal ions as active centers |
| ATE530520T1 (de) | 2001-08-10 | 2011-11-15 | Shionogi & Co | Antivirales mittel |
| US6727275B2 (en) | 2001-10-03 | 2004-04-27 | Ucb, S.A./N.V. | Pyrrolidinone derivatives |
| CA2463976C (en) | 2001-10-26 | 2007-02-13 | Benedetta Crescenzi | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase |
| DE60231425D1 (de) | 2001-11-13 | 2009-04-16 | Shiseido Co Ltd | Azabicycloverbindung, matrixmetallproteaseinhibitor und zubereitung für haut |
| WO2004004657A2 (en) | 2002-07-09 | 2004-01-15 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
| CA2498111A1 (en) | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors |
| CA2470365C (en) | 2002-11-20 | 2011-05-17 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| PL408254A1 (pl) | 2003-01-14 | 2014-07-21 | Gilead Sciences Inc. | Kompozycje i i sposoby wykorzystywane w skojarzonej terapii przeciwwirusowej |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| TW200528440A (en) | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
| CN101014571A (zh) | 2004-01-30 | 2007-08-08 | 默克公司 | 用作hiv整合酶抑制剂的n－苄基－3,4－二羟基吡啶－2－羧酰胺类和n－苄基－2,3－二羟基吡啶－4－羧酰胺类化合物 |
| US7619086B2 (en) | 2004-03-09 | 2009-11-17 | Merck & Co., Inc. | HIV integrase inhibitors |
| EP1755586A2 (en) | 2004-04-29 | 2007-02-28 | The Regents of the University of California | Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors |
| WO2005110399A2 (en) | 2004-04-29 | 2005-11-24 | The Regents Of The University Of California | Zinc-binding groups for metalloprotein inhibitors |
| CA2564372C (en) | 2004-05-07 | 2011-10-11 | Merck & Co., Inc. | Hiv integrase inhibitors |
| US7273859B2 (en) | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
| WO2005113509A1 (en) | 2004-05-20 | 2005-12-01 | Japan Tobacco Inc. | Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| US8633219B2 (en) | 2004-05-21 | 2014-01-21 | Japan Tobacco Inc. | Combination therapy |
| EP1790638B1 (en) | 2004-09-15 | 2013-04-03 | Shionogi Co., Ltd. | Carbamoylpyridone derivative having hiv integrase inhibitory activity |
| WO2006066414A1 (en) | 2004-12-23 | 2006-06-29 | Virochem Pharma Inc. | Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase |
| WO2006088173A1 (ja) | 2005-02-21 | 2006-08-24 | Shionogi & Co., Ltd. | Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体 |
| PT3284520T (pt) | 2005-04-28 | 2019-09-10 | Shionogi & Co | Derivado policíclico de carbamoílpiridona possuindo atividade inibidora de integrase do hiv |
| TW200716632A (en) | 2005-05-16 | 2007-05-01 | Gilead Sciences Inc | Integrase inhibitor compounds |
| EP1906971A2 (en) | 2005-07-27 | 2008-04-09 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2007049675A1 (ja) | 2005-10-27 | 2007-05-03 | Shionogi & Co., Ltd. | Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体 |
| CA2847871C (en) | 2005-12-30 | 2016-07-26 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| WO2007089030A1 (en) | 2006-02-01 | 2007-08-09 | Japan Tobacco Inc. | Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection |
| WO2007102499A1 (ja) | 2006-03-06 | 2007-09-13 | Japan Tobacco Inc. | ４－オキソキノリン化合物の製造方法 |
| IN2014CN00613A (enExample) | 2006-03-06 | 2015-08-21 | Japan Tobacco Inc | |
| US7893055B2 (en) | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| EP2046328A4 (en) | 2006-07-19 | 2009-10-28 | Univ Georgia Res Found | PYRIDINONE DIKETOIC ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY |
| EP2395005A1 (en) | 2006-09-07 | 2011-12-14 | Industrial Research Limited | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases |
| ES2536923T3 (es) | 2006-09-12 | 2015-05-29 | Gilead Sciences, Inc. | Proceso e intermedios para preparar inhibidores de la integrasa del VIH |
| EP2084160A1 (en) | 2006-10-18 | 2009-08-05 | Merck & Co., Inc. | Hiv integrase inhibitors |
| LT2487166T (lt) | 2007-02-23 | 2016-11-10 | Gilead Sciences, Inc. | Terapinių agentų farmakokinetinių savybių moduliatoriai |
| US20080280945A1 (en) | 2007-05-09 | 2008-11-13 | Sachin Lohani | Crystalline forms of an HIV integrase inhibitor |
| AR067184A1 (es) | 2007-06-29 | 2009-09-30 | Gilead Sciences Inc | Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica |
| CN101686972B (zh) | 2007-06-29 | 2013-08-14 | 吉里德科学公司 | 治疗用组合物和方法 |
| AR068403A1 (es) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| EA201200631A1 (ru) | 2007-11-16 | 2012-11-30 | Джилид Сайенсиз, Инк. | Ингибиторы репликации вируса иммунодефицита человека |
| US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US20100272811A1 (en) | 2008-07-23 | 2010-10-28 | Alkermes,Inc. | Complex of trospium and pharmaceutical compositions thereof |
| EP2330902B1 (en) | 2008-07-25 | 2012-11-14 | GlaxoSmithKline LLC | Chemical compounds |
| EP2320909B8 (en) | 2008-07-25 | 2016-03-30 | VIIV Healthcare Company | Chemical compounds |
| EP2320908B9 (en) | 2008-07-25 | 2014-06-18 | VIIV Healthcare Company | Dolutegravir Prodrugs |
| WO2010011819A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| WO2010011818A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| WO2010011815A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| EP3210603A1 (en) | 2008-12-11 | 2017-08-30 | Shionogi & Co., Ltd | Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| WO2011028044A2 (ko) | 2009-09-02 | 2011-03-10 | 이화여자대학교 산학협력단 | 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물 |
| CA2967453C (en) | 2010-01-27 | 2018-07-17 | Viiv Healthcare Company | Combinations for use in the inhibition of hiv-1 |
| NZ601847A (en) | 2010-02-26 | 2014-03-28 | Japan Tobacco Inc | 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor |
| TWI582097B (zh) | 2010-03-23 | 2017-05-11 | Ｖｉｉｖ醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
| WO2011139637A1 (en) | 2010-05-03 | 2011-11-10 | Philadelphia Health & Education Corporation | Small-molecule modulators of hiv-1 capsid stability and methods thereof |
| AU2011274322B2 (en) | 2010-07-02 | 2015-08-13 | Gilead Sciences, Inc. | Naphth- 2 -ylacetic acid derivatives to treat AIDS |
| BR112012033689A2 (pt) | 2010-07-02 | 2019-09-24 | Gilead Sciences Inc | derivados de ácido 2-quinolinil-acético como compostos de hiv antivirais |
| SG187683A1 (en) | 2010-08-05 | 2013-03-28 | Shionogi & Co | Process for preparing compound having hiv integrase inhibitory activity |
| BR112013006722B1 (pt) | 2010-09-24 | 2020-11-03 | Shionogi & Co., Ltd | profármaco de derivado de carbamoilpiridona policíclica substituída |
| EA024952B1 (ru) | 2011-04-21 | 2016-11-30 | Джилид Сайэнс, Инк. | Бензотиазолы и их применение для лечения вич-инфекции |
| WO2012151361A1 (en) | 2011-05-03 | 2012-11-08 | Concert Pharmaceuticals Inc. | Carbamoylpyridone derivatives |
| US9328075B2 (en) | 2011-05-05 | 2016-05-03 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for treating influenza |
| EP2729448B1 (en) | 2011-07-06 | 2015-09-09 | Gilead Sciences, Inc. | Compounds for the treatment of hiv |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| WO2013038407A1 (en) | 2011-09-14 | 2013-03-21 | Mapi Pharma Ltd. | Amorphous form of dolutegravir |
| AU2012321762A1 (en) | 2011-10-12 | 2014-04-17 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase-inhibiting activity |
| WO2013090929A1 (en) | 2011-12-15 | 2013-06-20 | Gilead Sciences, Inc. | Amino quinoline derivatives inhibitors of hcv |
| ES2668422T3 (es) | 2012-04-20 | 2018-05-18 | Gilead Sciences, Inc. | Derivados del ácido benzotiazol-6-il acético y su uso para tratar una infección por VIH |
| WO2014008636A1 (en) | 2012-07-11 | 2014-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as hiv integrase inhibitors |
| EP2875024A4 (en) | 2012-07-20 | 2015-12-23 | Merck Sharp & Dohme | HIV TREATMENT WITH AMIDOSUBSTITUTED PYRIMIDINONE DERIVATIVES |
| WO2014018449A1 (en) | 2012-07-25 | 2014-01-30 | Merck Sharp & Dohme Corp. | Substituted naphthyridinedione derivatives as hiv integrase inhibitors |
| IN2015DN01688A (enExample) | 2012-08-03 | 2015-07-03 | Gilead Sciences Inc | |
| MX2015007563A (es) | 2012-12-14 | 2015-10-14 | Glaxosmithkline Llc | Composiciones farmaceuticas. |
| US9714243B2 (en) | 2012-12-17 | 2017-07-25 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as HIV integrase inhibitors |
| EA037633B1 (ru) | 2012-12-21 | 2021-04-23 | Джилид Сайэнс, Инк. | Полициклические карбамоилпиридоновые соединения, их фармацевтические композиции и применение |
| US20160000721A1 (en) | 2012-12-21 | 2016-01-07 | Merck Sharp & Dohme Corp. | Gastro-retentive formulations |
| US20140221355A1 (en) | 2012-12-21 | 2014-08-07 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| TW201431859A (zh) | 2012-12-27 | 2014-08-16 | Japan Tobacco Inc | 經取代之螺吡啶並［１，２－ａ］吡□衍生物及該衍生物作爲ＨＩＶ整合酶抑制劑之醫藥用途 |
| WO2014200880A1 (en) * | 2013-06-13 | 2014-12-18 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| CA2916993C (en) * | 2013-07-12 | 2019-01-15 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| NO2865735T3 (enExample) * | 2013-07-12 | 2018-07-21 | ||
| WO2015039348A1 (en) | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
| MD4794B1 (ro) | 2013-09-27 | 2022-02-28 | Merck Sharp & Dohme Corp | Derivaţi de chinolizină substituiţi utili ca inhibitori de integrază HIV |
| WO2015089847A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
-
2014
- 2014-07-11 CA CA2916993A patent/CA2916993C/en active Active
- 2014-07-11 AU AU2014286993A patent/AU2014286993B2/en active Active
- 2014-07-11 SM SM20170498T patent/SMT201700498T1/it unknown
- 2014-07-11 SI SI201430395T patent/SI3019503T1/sl unknown
- 2014-07-11 DK DK14745052.2T patent/DK3019503T3/da active
- 2014-07-11 PT PT171774334T patent/PT3252058T/pt unknown
- 2014-07-11 EP EP17177433.4A patent/EP3252058B1/en active Active
- 2014-07-11 PL PL14745052T patent/PL3019503T3/pl unknown
- 2014-07-11 WO PCT/US2014/046413 patent/WO2015006731A1/en not_active Ceased
- 2014-07-11 SI SI201431752T patent/SI3252058T1/sl unknown
- 2014-07-11 ES ES14745052.2T patent/ES2645192T3/es active Active
- 2014-07-11 ES ES17177433T patent/ES2859102T3/es active Active
- 2014-07-11 HU HUE14745052A patent/HUE037347T2/hu unknown
- 2014-07-11 JP JP2016525819A patent/JP6411491B2/ja active Active
- 2014-07-11 LT LTEP14745052.2T patent/LT3019503T/lt unknown
- 2014-07-11 US US14/329,694 patent/US9421214B2/en active Active
- 2014-07-11 PT PT147450522T patent/PT3019503T/pt unknown
- 2014-07-11 HR HRP20171808TT patent/HRP20171808T1/hr unknown
- 2014-07-11 EP EP14745052.2A patent/EP3019503B1/en active Active
- 2014-07-11 PL PL17177433T patent/PL3252058T3/pl unknown
- 2014-07-11 RS RS20171145A patent/RS56540B1/sr unknown
-
2015
- 2015-01-15 NO NO15151336A patent/NO3011851T3/no unknown
-
2016
- 2016-07-12 US US15/208,304 patent/US9700554B2/en active Active
-
2017
- 2017-06-09 US US15/618,464 patent/US20180153887A1/en not_active Abandoned
- 2017-11-02 CY CY20171101151T patent/CY1119544T1/el unknown
-
2018
- 2018-01-10 US US15/867,629 patent/US20190046526A1/en not_active Abandoned
- 2018-08-02 US US16/053,456 patent/US10668064B2/en active Active
- 2018-09-25 AU AU2018236731A patent/AU2018236731B2/en active Active
-
2020
- 2020-02-12 AU AU2020200996A patent/AU2020200996A1/en not_active Abandoned
-
2022
- 2022-02-14 US US17/671,402 patent/US20230087744A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6411491B2 (ja) | 多環式カルバモイルピリドン化合物およびｈｉｖ感染症を処置するためのその使用 | |
| US12521388B2 (en) | Substituted dipyrido[1,2-a:1′,2′-d]pyrazines for treating viral infections | |
| NZ716794B2 (en) | Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections | |
| HK1223616B (en) | Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections | |
| NZ716774B2 (en) | Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections | |
| HK1223615B (en) | Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170711 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170711 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180424 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180514 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180814 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180827 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180926 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6411491 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |